Literature DB >> 17653086

Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

L P Jones1, M T Tilli, S Assefnia, K Torre, E D Halama, A Parrish, E M Rosen, P A Furth.   

Abstract

BRCA1 can regulate estrogen receptor-alpha (ERalpha) activity. This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that exposure to increased estrogen or ERalpha collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Longer ductal extension was found in mammary glands of Brca1(f/f;MMTV-Cre) mice during puberty as compared to wild-type mice. Terminal end bud differentiation was impaired in Brca1 mutant mice with preservation of prolactin-induced alveolar differentiation. Exogenous estrogen stimulated an abnormal sustained increase in mammary epithelial cell proliferation and the appearance of ERalpha-negative preneoplasia in postpubertal Brca1 mutant mice. Carcinogenesis was investigated using Brca1(f/f;MMTV-Cre) mice hemizygous for p53. Exogenous estrogen increased the percentage of mice with multiple hyperplastic alveolar nodules. Targeted conditional ERalpha overexpression in mammary epithelial cells of mice that were Brca1 mutant and hemizygous for p53 increased the percentage of mice exhibiting multiple hyperplastic nodules, invasive mammary cancers and cancer multiplicity. Significantly more than half of the preneoplasia and cancers were ERalpha negative even as their initiation was promoted by ERalpha overexpression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653086      PMCID: PMC3045705          DOI: 10.1038/sj.onc.1210674

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.

Authors:  Saori Furuta; Xianzhi Jiang; Bingnan Gu; Eric Cheng; Phang-Lang Chen; Wen-Hwa Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

2.  Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells.

Authors:  M F El Etreby; Y Liang; R W Wrenn; P V Schoenlein
Journal:  Breast Cancer Res Treat       Date:  1998-09       Impact factor: 4.872

3.  Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486).

Authors:  Tomasz Milewicz; Ewa Lucja Gregoraszczuk; Krystyna Sztefko; Katarzyna Augustowska; Józef Krzysiek; Janusz Ryś
Journal:  Growth Horm IGF Res       Date:  2005-04       Impact factor: 2.372

4.  Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action.

Authors:  Weifeng Ruan; Marie E Monaco; David L Kleinberg
Journal:  Endocrinology       Date:  2004-12-16       Impact factor: 4.736

5.  Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene.

Authors:  L Vassen; W Wegrzyn; L Klein-Hitpass
Journal:  Mol Endocrinol       Date:  1999-03

6.  Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature.

Authors:  Saori Furuta; Ju-Ming Wang; Shuanzeng Wei; Yung-Ming Jeng; Xianzhi Jiang; Bingnan Gu; Phang-Lang Chen; Eva Y-H P Lee; Wen-Hwa Lee
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

7.  Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.

Authors:  Andrew J Deans; Kaylene J Simpson; Melanie K Trivett; Melissa A Brown; Grant A McArthur
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

8.  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Authors:  William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.

Authors:  M S Frech; L P Jones; P A Furth
Journal:  Breast Cancer Online       Date:  2005-08-01

10.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  42 in total

1.  Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.

Authors:  Pascal Pujol; Christine Lasset; Pascaline Berthet; Catherine Dugast; Suzette Delaloge; Jean-Pierre Fricker; Isabelle Tennevet; Nathalie Chabbert-Buffet; Pascale This; Karen Baudry; Jerome Lemonnier; Lise Roca; Sylvie Mijonnet; Paul Gesta; Jean Chiesa; Helene Dreyfus; Philippe Vennin; Capucine Delnatte; Yves Jean Bignon; Alain Lortholary; Fabienne Prieur; Laurence Gladieff; Anne Lesur; Krishna B Clough; Catherine Nogues; Anne-Laure Martin
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

2.  Loss of BRCA1 leads to an increased sensitivity to Bisphenol A.

Authors:  Laundette P Jones; Aishia Sampson; Hyo Jin Kang; Hee Jeong Kim; Yong-Weon Yi; Sun Young Kwon; Janice K Babus; Antai Wang; Insoo Bae
Journal:  Toxicol Lett       Date:  2010-09-22       Impact factor: 4.372

3.  Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

Authors:  Yongxian Ma; York Tomita; Anju Preet; Robert Clarke; Erikah Englund; Scott Grindrod; Shyam Nathan; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2014-12

4.  Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer.

Authors:  Rebecca E Nakles; Sarah L Millman; M Carla Cabrera; Peter Johnson; Susette Mueller; Philipp S Hoppe; Timm Schroeder; Priscilla A Furth
Journal:  J Vis Exp       Date:  2013-02-08       Impact factor: 1.355

5.  BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.

Authors:  Shyam Nathan; Yongxian Ma; York A Tomita; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Breast Cancer Res Treat       Date:  2017-08-14       Impact factor: 4.872

Review 6.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

7.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

8.  BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.

Authors:  Yongxian Ma; Saijun Fan; Changyan Hu; Qinghui Meng; Suzanne A Fuqua; Richard G Pestell; York A Tomita; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2009-11-03

9.  A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.

Authors:  Aleata A Triplett; Cristina Montagna; Kay-Uwe Wagner
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 10.  BRCA1, hormone, and tissue-specific tumor suppression.

Authors:  Yanfen Hu
Journal:  Int J Biol Sci       Date:  2008-12-13       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.